These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36852700)

  • 1. Hypermethylation-Mediated lncRNA MAGI2-AS3 Downregulation Facilitates Malignant Progression of Laryngeal Squamous Cell Carcinoma via Interacting With SPT6.
    Wang J; Yang C; Cao H; Yang J; Meng W; Yu M; Yu L; Wang B
    Cell Transplant; 2023; 32():9636897231154574. PubMed ID: 36852700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomal long noncoding RNAs MAGI2-AS3 and CCDC144NL-AS1 in oral squamous cell carcinoma development via the PI3K-AKT-mTOR signaling pathway.
    Li C; Guo H; Xiong J; Feng B; Zhu P; Jiang W; Jiang P; Su X; Huang X
    Pathol Res Pract; 2022 Dec; 240():154219. PubMed ID: 36401978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation-mediated downregulation of the LINC01554 gene accelerates the malignant progression and regulates the chemosensitivity of laryngeal squamous cell carcinoma.
    Wang J; Meng W; Yang J; Cao H; Liu T; Yang C; Yu M; Wang B
    J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 35988928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of lncRNA MAGI2-AS3 in human cancers.
    Kai-Xin L; Cheng C; Rui L; Zheng-Wei S; Wen-Wen T; Peng X
    Biomed Pharmacother; 2021 Sep; 141():111812. PubMed ID: 34126355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA MAGI2-AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR-374b-5p/SMG1 signaling pathway.
    Yin Z; Ma T; Yan J; Shi N; Zhang C; Lu X; Hou B; Jian Z
    J Cell Physiol; 2019 Aug; 234(10):18825-18836. PubMed ID: 30924168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant methylation‑mediated decrease of lncRNA HNF1A‑AS1 contributes to malignant progression of laryngeal squamous cell carcinoma via EMT.
    Shi Y; Zhang Q; Xie M; Feng Y; Ma S; Yi C; Wang Z; Li Y; Liu X; Liu H; Yang H; Yan Y; Zhang Y; Ren X; Luo H
    Oncol Rep; 2020 Dec; 44(6):2503-2516. PubMed ID: 33125127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA MAGI2-AS3 is downregulated in the distant recurrence of hepatocellular carcinoma after surgical resection and affects migration and invasion via ROCK2.
    Fang G; Wang J; Sun X; Xu R; Zhao X; Shao L; Sun C; Wang Y
    Ann Hepatol; 2020; 19(5):535-540. PubMed ID: 32546442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA MAGI2-AS3 is downregulated in non-small cell lung cancer and may be a sponge of miR-25.
    Sui Y; Chi W; Feng L; Jiang J
    BMC Pulm Med; 2020 Mar; 20(1):59. PubMed ID: 32138716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axis.
    Yang G; Li T; Liu J; Quan Z; Liu M; Guo Y; Wu Y; Ou L; Wu X; Zheng Y
    Genomics; 2023 Mar; 115(2):110599. PubMed ID: 36889366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA MAGI2-AS3 inhibits bladder cancer progression through MAGI2/PTEN/epithelial-mesenchymal transition (EMT) axis.
    Shen D; Xu J; Cao X; Cao X; Tan H; Deng H
    Cancer Biomark; 2021; 30(2):155-165. PubMed ID: 33104021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA MAGI2-AS3 inhibites tumor progression by up-regulating STAM via interacting with miR-142-3p in clear cell renal cell carcinoma.
    Yang R; Chen Z; Ao S; Liang L; Chen Z; Duan X; Zeng G; Deng T
    Cell Signal; 2024 Jan; 113():110954. PubMed ID: 38084836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis.
    Hao XZ; Yang K
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7399-7407. PubMed ID: 31539127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA MAGI2-AS3 inhibits tumor progression and angiogenesis by regulating ACY1 via interacting with transcription factor HEY1 in clear cell renal cell carcinoma.
    Wang G; Li H; Hou Y
    Cancer Gene Ther; 2022 May; 29(5):585-596. PubMed ID: 34002044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA MAGI2-AS3 inhibits bladder cancer progression by targeting the miR-31-5p/TNS1 axis.
    Tang C; Cai Y; Jiang H; Lv Z; Yang C; Xu H; Li Z; Li Y
    Aging (Albany NY); 2020 Nov; 12(24):25547-25563. PubMed ID: 33231563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA MAGI2-AS3 is down-regulated in intervertebral disc degeneration and participates in the regulation of FasL expression in nucleus pulposus cells.
    Cui S; Liu Z; Tang B; Wang Z; Li B
    BMC Musculoskelet Disord; 2020 Mar; 21(1):149. PubMed ID: 32143617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia.
    Chen L; Fan X; Zhu J; Chen X; Liu Y; Zhou H
    RNA Biol; 2020 Jun; 17(6):784-793. PubMed ID: 32174258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long noncoding RNA MAGI2-AS3/miR-218-5p/GDPD5/SEC61A1 axis drives cellular proliferation and migration and confers cisplatin resistance in nasopharyngeal carcinoma.
    Cao C; Zhou S; Hu J
    Int Forum Allergy Rhinol; 2020 Aug; 10(8):1012-1023. PubMed ID: 32450008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel insights for lncRNA MAGI2-AS3 in solid tumors.
    Xue C; Li G; Lu J; Luo J; Jia J
    Biomed Pharmacother; 2021 May; 137():111429. PubMed ID: 33761624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA
    Li F; Hu Q; Pang Z; Xu X
    Cancer Biother Radiopharm; 2020 Feb; 35(1):72-76. PubMed ID: 31910343
    [No Abstract]   [Full Text] [Related]  

  • 20. MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2.
    Xu X; Yuan X; Ni J; Guo J; Gao Y; Yin W; Li F; Wei L; Zhang J
    J Cell Physiol; 2021 Feb; 236(2):1116-1130. PubMed ID: 32730644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.